Education
About Us
Working with TipRanks
Follow Us
Merck & Company (MRK)
NYSE:MRK
MRK Analyst Ratings
Moderate Buy
11 Buy
6 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
MRK Stock 12 Month Forecast
Average Price Target
$111.88
▲(25.38% Upside)
| Highest Price Target$138.00 | Average Price Target$111.88 | Lowest Price Target$95.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Citi
Reiterated
03/25/25
Berenberg Bank
Reiterated
03/11/25
Bernstein
Reiterated
03/05/25
Jefferies
Reiterated
02/23/25
Morgan Stanley
Reiterated
02/23/25
Deutsche Bank
Downgraded
02/18/25
Guggenheim
Reiterated
02/12/25
TD Cowen
Downgraded
02/10/25
BMO Capital
$105→$96
Hold
7.59%
Upside
Reiterated
02/05/25
Merck price target lowered to $96 from $105 at BMO CapitalMerck price target lowered to $96 from $105 at BMO Capital
Bank of America Securities
$118→$112
Buy
25.52%
Upside
Reiterated
02/05/25
Merck & Co. Stock: Undervalued with Promising Long-Term Prospects Justifying a Buy RatingWe suggested MRK give LT financial guidance at some point, like other co’s sometimes do, but it’s unclear if this is in the cards. We also asked about near-term competitor data sets to Keytruda making investors nervous (AZN AVANZAR trial; Summit PD1xVEGF) – MRK didn’t clearly address the former, and on the latter raised the specter of Summit not hitting overall survival (if true, a win for MRK). Net, MRK didn’t give enough assurances across multiple fronts to help lift the stock up from its intra-day price decline (-10%) vs yesterday – and the stock price reaction is not surprising.
J.P. Morgan
$145→$130
Buy
45.69%
Upside
Reiterated
02/05/25
J.P. Morgan Keeps Their Buy Rating on Merck & Company (MRK)
Evercore ISI
―
Buy
―
Reiterated
02/05/25
Evercore ISI Reaffirms Their Buy Rating on Merck & Company (MRK)
Leerink Partners
$118→$113
Buy
26.64%
Upside
Reiterated
02/05/25
Merck's Broad Pipeline and Upcoming Catalysts Offer Upside Despite Investor Concerns
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Citi
Reiterated
03/25/25
Berenberg Bank
Reiterated
03/11/25
Bernstein
Reiterated
03/05/25
Jefferies
Reiterated
02/23/25
Morgan Stanley
Reiterated
02/23/25
Deutsche Bank
Downgraded
02/18/25
Guggenheim
Reiterated
02/12/25
TD Cowen
Downgraded
02/10/25
BMO Capital
$105→$96
Hold
7.59%
Upside
Reiterated
02/05/25
Merck price target lowered to $96 from $105 at BMO CapitalMerck price target lowered to $96 from $105 at BMO Capital
Bank of America Securities
$118→$112
Buy
25.52%
Upside
Reiterated
02/05/25
Merck & Co. Stock: Undervalued with Promising Long-Term Prospects Justifying a Buy RatingWe suggested MRK give LT financial guidance at some point, like other co’s sometimes do, but it’s unclear if this is in the cards. We also asked about near-term competitor data sets to Keytruda making investors nervous (AZN AVANZAR trial; Summit PD1xVEGF) – MRK didn’t clearly address the former, and on the latter raised the specter of Summit not hitting overall survival (if true, a win for MRK). Net, MRK didn’t give enough assurances across multiple fronts to help lift the stock up from its intra-day price decline (-10%) vs yesterday – and the stock price reaction is not surprising.
J.P. Morgan
$145→$130
Buy
45.69%
Upside
Reiterated
02/05/25
J.P. Morgan Keeps Their Buy Rating on Merck & Company (MRK)
Evercore ISI
―
Buy
―
Reiterated
02/05/25
Evercore ISI Reaffirms Their Buy Rating on Merck & Company (MRK)
Leerink Partners
$118→$113
Buy
26.64%
Upside
Reiterated
02/05/25
Merck's Broad Pipeline and Upcoming Catalysts Offer Upside Despite Investor Concerns
MRK Analyst Recommendation Trends
Rating
Nov 24
Dec 24
Jan 25
Feb 25
Mar 25
Strong Buy
3
4
5
3
2
Buy
30
24
24
26
24
Hold
13
16
19
20
17
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
46
44
48
49
43
Each month's total comprises the sum of three months' worth of ratings.
MRK Financial Forecast
MRK Stock Forecast FAQ
What is MRK’s average 12-month price target, according to analysts?
Based on analyst ratings, Merck & Company’s 12-month average price target is $111.88.
What is MRK’s upside potential, based on the analysts’ average price target?
Merck & Company has 25.38% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is MRK a Buy, Sell or Hold?
Merck & Company has a consensus rating of Moderate Buy which is based on 11 buy ratings, 6 hold ratings and 0 sell ratings.
What is Merck & Company’s price target?
The average price target for Merck & Company is $111.88. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $138.00 ,the lowest forecast is $95.00. The average price target represents 25.38% Increase from the current price of $89.23.
The highest analyst price target is $138.00 ,the lowest forecast is $95.00. The average price target represents 25.38% Increase from the current price of $89.23.
What do analysts say about Merck & Company?
Merck & Company’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 17 Wall Streets Analysts.
How can I buy shares of MRK?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.